Abstract
Antimicrobial resistance is a key public health concern of our era due to an ever-increasing number of drug-resistant pathogens, including several Gram-negative bacilli. The latter are endowed with a low permeable outer membrane and with numerous chromosomally encoded multidrug efflux pumps, which are not only ubiquitous but also polyspecific, thus recognizing a broad range of compounds. Efflux pumps are a major defense mechanism of these organisms against antimicrobials as they can significantly increase the levels of resistance by allowing time for the organisms to develop specific resistance mechanisms. One of the potential strategies to reinvigorate the efficacy of antimicrobials is by joint administration with efflux pump inhibitors, which either block the substrate binding and/or hinder any of the transport-dependent steps of the pumps. In this chapter, we provide an overview of multidrug resistance efflux pumps, their inhibition strategies, and the important findings from the various computational simulation studies reported to date with respect to the rational design of inhibitors and on deciphering their mechanism of action.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fauci AS (2001) Infectious diseases: considerations for the 21st century. Clin Infect Dis 32:675–685. doi:10.1086/319235
World Health Organization (2014) Antimicrobial resistance: global report on surveillance. World Health Organization, Geneva
Howell L (2013) Global risks 2013: an initiative of the risk response network, 8th edn. World Economic Forum, Geneva
Butler MS, Cooper MA (2011) Antibiotics in the clinical pipeline in 2011. J Antibiot (Tokyo) 64:413–425. doi:10.1038/ja.2011.44
Nikaido H (1994) Prevention of drug access to bacterial targets: permeability barriers and active efflux. Science 264:382–388. doi:10.1126/science.8153625
Poole K (2005) Efflux-mediated antimicrobial resistance. J Antimicrob Chemother 56:20–51. doi:10.1093/jac/dki171
Piddock LJ (2006) Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin Microbiol Rev 19:382–402. doi:10.1128/CMR.19.2.382-402.2006
Nikaido H, Pagès JM (2012) Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol Rev 36:340–363. doi:10.1111/j.1574-6976.2011.00290.x
Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ (2015) Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol 13:42–51. doi:10.1038/nrmicro3380
Lomovskaya O, Bostian KA (2006) Practical applications and feasibility of efflux pump inhibitors in the clinic – a vision for applied use. Biochem Pharmacol 71:910–918. doi:10.1016/j.bcp.2005.12.008
Blair JM, Richmond GE, Piddock LJ (2014) Multidrug efflux pumps in Gram-negative bacteria and their role in antibiotic resistance. Future Microbiol 9:1165–1177. doi:10.2217/fmb.14.66
Li X-Z, Nikaido H (2009) Efflux-mediated drug resistance in bacteria: an update. Drugs 69:1555–1623. doi:10.2165/11317030-000000000-00000
Zhang H, Wang Y-J, Zhang Y-K, Wang D-S, Kathawala RJ, Patel A, Talele TT, Chen Z-S et al (2014) AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. Cancer Lett 350:61–68. doi:10.1016/j.canlet.2014.04.008
Martinez L, Arnaud O, Henin E, Tao H, Chaptal V, Doshi R, Andrieu T, Dussurgey S et al (2014) Understanding polyspecificity within the substrate‐binding cavity of the human multidrug resistance P‐glycoprotein. FEBS J 281:673–682. doi:10.1111/febs.12613
Kim J-Y, Henrichs S, Bailly A, Vincenzetti V, Sovero V, Mancuso S, Pollmann S, Kim D et al (2010) Identification of an ABCB/P-glycoprotein-specific inhibitor of auxin transport by chemical genomics. J Biol Chem 285:23309–23317. doi:10.1074/jbc.M110.105981
Michaelis M, Rothweiler F, Nerreter T, Van Rikxoort M, Sharifi M, Wiese M, Ghafourian T, Cinatl J (2014) Differential effects of the oncogenic BRAF inhibitor PLX4032 (vemurafenib) and its progenitor PLX4720 on ABCB1 function. J Pharm Pharm Sci 17:154–168
Singh DV, Godbole MM, Misra K (2013) A plausible explanation for enhanced bioavailability of P-gp substrates in presence of piperine: simulation for next generation of P-gp inhibitors. J Mol Model 19:227–238. doi:10.1007/s00894-012-1535-8
Liu D-L, Li Y-J, Yao N, Xu J, Chen Z-S, Yiu A, Zhang C-X, Ye W-C et al (2014) Acerinol, a cyclolanstane triterpenoid from Cimicifuga acerina, reverses ABCB1-mediated multidrug resistance in HepG2/ADM and MCF-7/ADR cells. Eur J Pharmacol 733:34–44. doi:10.1016/j.ejphar.2014.03.043
Klepsch F, Vasanthanathan P, Ecker GF (2014) Ligand and structure-based classification models for prediction of P-glycoprotein inhibitors. J Chem Inf Model 54:218–229. doi:10.1021/ci400289j
Zha W, Wang G, Xu W, Liu X, Wang Y, Zha BS, Shi J, Zhao Q et al (2013) Inhibition of P-glycoprotein by HIV protease inhibitors increases intracellular accumulation of berberine in murine and human macrophages. PLoS One 8:e54349. doi:10.1371/journal.pone.0054349
Zhao X-Q, Xie J-D, X-g C, Sim HM, Zhang X, Liang Y-J, Singh S, Talele TT et al (2012) Neratinib reverses ATP-binding cassette B1-mediated chemotherapeutic drug resistance in vitro, in vivo, and ex vivo. Mol Pharmacol 82:47–58. doi:10.1124/mol.111.076299
Hamm R, Sugimoto Y, Steinmetz H, Efferth T (2014) Resistance mechanisms of cancer cells to the novel vacuolar H+-ATPase inhibitor archazolid B. Invest New Drugs 32:893–903. doi:10.1007/s10637-014-0134-1
Matsson P, Pedersen JM, Norinder U, Bergström CA, Artursson P (2009) Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs. Pharm Res 26:1816–1831. doi:10.1007/s11095-009-9896-0
Abdelfatah SA, Efferth T (2015) Cytotoxicity of the indole alkaloid reserpine from Rauwolfia serpentina against drug-resistant tumor cells. Phytomedicine 22:308–318. doi:10.1016/j.phymed.2015.01.002
Munagala S, Sirasani G, Kokkonda P, Phadke M, Krynetskaia N, Lu P, Sharom FJ, Chaudhury S et al (2014) Synthesis and evaluation of Strychnos alkaloids as MDR reversal agents for cancer cell eradication. Bioorg Med Chem 22:1148–1155. doi:10.1016/j.bmc.2013.12.022
Brewer FK, Follit CA, Vogel PD, Wise JG (2014) In silico screening for inhibitors of P-glycoprotein that target the nucleotide binding domains. Mol Pharmacol 86:716–726. doi:10.1124/mol.114.095414
Kim N, Shin J-M, No KT (2014) In silico study on the interaction between P-glycoprotein and its inhibitors at the drug binding pocket. Bull Korean Chem Soc 35:2317–2325. doi:10.5012/bkcs.2014.35.8.2317
Upadhyay HC, Dwivedi GR, Roy S, Sharma A, Darokar MP, Srivastava SK (2014) Phytol derivatives as drug resistance reversal agents. ChemMedChem 9:1860–1868. doi:10.1002/cmdc.201402027
Zeino M, Saeed ME, Kadioglu O, Efferth T (2014) The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein – a well-known, yet poorly understood drug transporter. Invest New Drugs 32:618–625. doi:10.1007/s10637-014-0098-1
Silva R, Carmo H, Vilas-Boas V, Barbosa DJ, Palmeira A, Sousa E, Carvalho F, de Lourdes Bastos M et al (2014) Colchicine effect on P-glycoprotein expression and activity: in silico and in vitro studies. Chem Biol Interact 218:50–62. doi:10.1016/j.cbi.2014.04.009
Kathawala RJ, Chen J-J, Zhang Y-K, Wang Y-J, Patel A, Wang D-S, Talele TT, Ashby CR et al (2014) Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance. Int J Oncol 44:1634–1642. doi:10.3892/ijo.2014.2341
Dwivedi GR, Upadhyay HC, Yadav DK, Singh V, Srivastava SK, Khan F, Darmwal NS, Darokar MP (2014) 4‐Hydroxy‐α‐tetralone and its derivative as drug resistance reversal agents in multi drug resistant Escherichia coli. Chem Biol Drug Des 83:482–492. doi:10.1111/cbdd.12263
Tajima Y, Nakagawa H, Tamura A, Kadioglu O, Satake K, Mitani Y, Murase H, Regasini LO et al (2014) Nitensidine A, a guanidine alkaloid from Pterogyne nitens, is a novel substrate for human ABC transporter ABCB1. Phytomedicine 21:323–332. doi:10.1016/j.phymed.2013.08.024
Tan W, Mei H, Chao L, Liu T, Pan X, Shu M, Yang L (2013) Combined QSAR and molecule docking studies on predicting P-glycoprotein inhibitors. J Comput Aided Mol Des 27:1067–1073. doi:10.1007/s10822-013-9697-8
Ferreira RJ, Ferreira M-JU, dos Santos DJ (2013) Molecular docking characterizes substrate-binding sites and efflux modulation mechanisms within P-glycoprotein. J Chem Inf Model 53:1747–1760. doi:10.1021/ci400195v
Tiwari AK, Sodani K, C-l D, Abuznait AH, Singh S, Xiao Z-J, Patel A, Talele TT et al (2013) Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer Lett 328:307–317. doi:10.1016/j.canlet.2012.10.001
Chufan EE, Kapoor K, Sim H-M, Singh S, Talele TT, Durell SR, Ambudkar SV (2013) Multiple transport-active binding sites are available for a single substrate on human P-glycoprotein (ABCB1). PLoS One 8:e82463. doi:10.1371/journal.pone.0082463
Kanaoka S, Kimura Y, Fujikawa M, Nakagawa Y, Ueda K, Akamatsu M (2013) Substrate recognition by P-glycoprotein efflux transporters: structure-ATPase activity relationship of diverse chemicals and agrochemicals. J Pest Sci 38:112–122. doi:10.1584/jpestics.D13-022
Zhang D-M, Shu C, Chen J-J, Sodani K, Wang J, Bhatnagar J, Lan P, Ruan Z-X et al (2012) BBA, a derivative of 23-hydroxybetulinic acid, potently reverses ABCB1-mediated drug resistance in vitro and in vivo. Mol Pharm 9:3147–3159. doi:10.1021/mp300249s
Dolghih E, Bryant C, Renslo AR, Jacobson MP (2011) Predicting binding to P-glycoprotein by flexible receptor docking. PLoS Comput Biol 7:e1002083. doi:10.1371/journal.pcbi.1002083
Kalia NP, Mahajan P, Mehra R, Nargotra A, Sharma JP, Koul S, Khan IA (2012) Capsaicin, a novel inhibitor of the NorA efflux pump, reduces the intracellular invasion of Staphylococcus aureus. J Antimicrob Chemother 67:2401–2408. doi:10.1093/jac/dks232
Xiao Z-P, Wang X-D, Wang P-F, Zhou Y, Zhang J-W, Zhang L, Zhou J, Zhou S-S et al (2014) Design, synthesis, and evaluation of novel fluoroquinolone–flavonoid hybrids as potent antibiotics against drug-resistant microorganisms. Eur J Med Chem 80:92–100. doi:10.1016/j.ejmech.2014.04.037
George AM (1996) Multidrug resistance in enteric and other Gram-negative bacteria. FEMS Microbiol Lett 139:1–10. doi:10.1111/j.1574-6968.1996.tb08172.x
Pagès J-M, Amaral L (2009) Mechanisms of drug efflux and strategies to combat them: challenging the efflux pump of Gram-negative bacteria. Biochim Biophys Acta 1794:826–833. doi:10.1016/j.bbapap.2008.12.011
Upadhyay R (2011) Emergence of drug resistance in microbes, its dissemination and target modification of antibiotics: a life threatening problem to human society. Int J Pharm Biol Res 2:119–126
Utsui Y, Yokota T (1985) Role of an altered penicillin-binding protein in methicillin-and cephem-resistant Staphylococcus aureus. Antimicrob Agents Chemother 28:397–403. doi:10.1128/AAC.28.3.397
Li X-Z, Plésiat P, Nikaido H (2015) The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin Microbiol Rev 28:337–418. doi:10.1128/CMR.00117-14
Sapunaric FM, Aldema-Ramos M, McMurry LM (2005) Tetracycline resistance: efflux, mutation, and other mechanisms. In: White DG, Alekshun MN, McDermot PF (eds) Frontiers in antimicrobial resistance, a tribute to Stuart B. Levy. ASM Press, Washington, DC, pp 3–18
Ruggerone P, Murakami S, Pos KM, Vargiu AV (2013) RND efflux pumps: structural information translated into function and inhibition mechanisms. Curr Top Med Chem 13:3079–3100. doi:10.2174/15680266113136660220
Blair JM, Bavro VN, Ricci V, Modi N, Cacciotto P, Kleinekathfer U, Ruggerone P, Vargiu AV et al (2015) AcrB drug-binding pocket substitution confers clinically relevant resistance and altered substrate specificity. Proc Natl Acad Sci U S A 112:3511–3516. doi:10.1073/pnas.1419939112
Piddock LJ (2006) Multidrug-resistance efflux pumps – not just for resistance. Nat Rev Microbiol 4:629–636. doi:10.1038/nrmicro1464
Rosner JL, Martin RG (2009) An excretory function for the Escherichia coli outer membrane pore TolC: upregulation of marA and soxS transcription and Rob activity due to metabolites accumulated in tolC mutants. J Bacteriol 191:5283–5292. doi:10.1128/JB.00507-09
Paul S, Alegre KO, Holdsworth SR, Rice M, Brown JA, McVeigh P, Kelly SM, Law CJ (2014) A single-component multidrug transporter of the major facilitator superfamily is part of a network that protects Escherichia coli from bile salt stress. Mol Microbiol 92:872–884. doi:10.1111/mmi.12597
Guelfo JR, Rodriguez-Rojas A, Matic I, Blazquez J (2010) A MATE-family efflux pump rescues the Escherichia coli 8-oxoguanine-repair-deficient mutator phenotype and protects against H2O2 killing. PLoS Genet 6:e1000931. doi:10.1371/journal.pgen.1000931
Bogomolnaya LM, Andrews KD, Talamantes M, Maple A, Ragoza Y, Vazquez-Torres A, Andrews-Polymenis H (2013) The ABC-type efflux pump MacAB protects Salmonella enterica serovar Typhimurium from oxidative stress. mBio 4:e00630-13. doi:10.1128/mBio.00630-13
Poole K (2012) Stress responses as determinants of antimicrobial resistance in Gram-negative bacteria. Trends Microbiol 20:227–234. doi:10.1016/j.tim.2012.02.004
Podnecky NL, Rhodes KA, Schweizer HP (2015) Efflux pump-mediated drug resistance in Burkholderia. Front Microbiol 6:305. doi:10.3389/fmicb.2015.00305
Baugh S, Phillips CR, Ekanayaka AS, Piddock LJ, Webber MA (2014) Inhibition of multidrug efflux as a strategy to prevent biofilm formation. J Antimicrob Chemother 69:673–681. doi:10.1093/jac/dkt420
Matsumura K, Furukawa S, Ogihara H, Morinaga Y (2011) Roles of multidrug efflux pumps on the biofilm formation of Escherichia coli K-12. Biocontrol Sci 16:69–72. doi:10.4265/bio.16.69
Saier MH Jr, Reddy VS, Tamang DG, Vastermark A (2014) The transporter classification database. Nucleic Acids Res 42:D251–D258. doi:10.1093/nar/gkt1097
Ren Q, Chen K, Paulsen IT (2007) TransportDB: a comprehensive database resource for cytoplasmic membrane transport systems and outer membrane channels. Nucleic Acids Res 35:D274–D279. doi:10.1093/nar/gkl925
Eswaran J, Koronakis E, Higgins MK, Hughes C, Koronakis V (2004) Three’s company: component structures bring a closer view of tripartite drug efflux pumps. Curr Opin Struct Biol 14:741–747. doi:10.1016/j.sbi.2004.10.003
Du D, van Veen HW, Murakami S, Pos KM, Luisi BF (2015) Structure, mechanism and cooperation of bacterial multidrug transporters. Curr Opin Struct Biol 33:76–91. doi:10.1016/j.sbi.2015.07.015
Higgins CF (2001) ABC transporters: physiology, structure and mechanism – an overview. Res Microbiol 152:205–210. doi:10.1016/S0923-2508(01)01193-7
Shapiro AB, Fox K, Lam P, Ling V (1999) Stimulation of P‐glycoprotein‐mediated drug transport by prazosin and progesterone. Eur J Biochem 259:841–850. doi:10.1046/j.1432-1327.1999.00098.x
Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R (2000) Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58:624–632. doi:10.1124/mol.58.3.624
Higgins CF, Linton KJ (2004) The ATP switch model for ABC transporters. Nat Struct Mol Biol 11:918–926. doi:10.1038/nsmb836
Lu M, Symersky J, Radchenko M, Koide A, Guo Y, Nie R, Koide S (2013) Structures of a Na+-coupled, substrate-bound MATE multidrug transporter. Proc Natl Acad Sci U S A 110:2099–2104. doi:10.1073/pnas.1219901110
Schuldiner S (2012) Undecided membrane proteins insert in random topologies. Up, down and sideways: it does not really matter. Trends Biochem Sci 37:215–219. doi:10.1016/j.tibs.2012.02.006
Martin C, Berridge G, Mistry P, Higgins C, Charlton P, Callaghan R (2000) Drug binding sites on P-glycoprotein are altered by ATP binding prior to nucleotide hydrolysis. Biochemistry 39:11901–11906. doi:10.1021/bi000559b
McDevitt CA, Crowley E, Hobbs G, Starr KJ, Kerr ID, Callaghan R (2008) Is ATP binding responsible for initiating drug translocation by the multidrug transporter ABCG2? FEBS J 275:4354–4362. doi:10.1111/j.1742-4658.2008.06578.x
Yan N (2013) Structural advances for the major facilitator superfamily (MFS) transporters. Trends Biochem Sci 38:151–159. doi:10.1016/j.tibs.2013.01.003
Lee A, Mao W, Warren MS, Mistry A, Hoshino K, Okumura R, Ishida H, Lomovskaya O (2000) Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance. J Bacteriol 182:3142–3150. doi:10.1128/JB.182.11.3142-3150.2000
Tal N, Schuldiner S (2009) A coordinated network of transporters with overlapping specificities provides a robust survival strategy. Proc Natl Acad Sci U S A 106:9051–9056. doi:10.1073/pnas.0902400106
Lewinson O, Adler J, Sigal N, Bibi E (2006) Promiscuity in multidrug recognition and transport: the bacterial MFS Mdr transporters. Mol Microbiol 61:277–284. doi:10.1111/j.1365-2958.2006.05254.x
Fluman N, Ryan CM, Whitelegge JP, Bibi E (2012) Dissection of mechanistic principles of a secondary multidrug efflux protein. Mol Cell 47:777–787. doi:10.1016/j.molcel.2012.06.018
Nikaido H, Zgurskaya HI (1999) Antibiotic efflux mechanisms. Curr Opin Infect Dis 12:529–536
Kuroda T, Tsuchiya T (2009) Multidrug efflux transporters in the MATE family. Biochim Biophys Acta 1794:763–768. doi:10.1016/j.bbapap.2008.11.012
He X, Szewczyk P, Karyakin A, Evin M, Hong WX, Zhang Q, Chang G (2010) Structure of a cation-bound multidrug and toxic compound extrusion transporter. Nature 467:991–994. doi:10.1038/nature09408
Tanaka Y, Hipolito CJ, Maturana AD, Ito K, Kuroda T, Higuchi T, Katoh T, Kato HE et al (2013) Structural basis for the drug extrusion mechanism by a MATE multidrug transporter. Nature 496:247–251. doi:10.1038/nature12014
Paulsen IT, Skurray RA, Tam R, Saier MH Jr, Turner RJ, Weiner JH, Goldberg EB, Grinius LL (1996) The SMR family: a novel family of multidrug efflux proteins involved with the efflux of lipophilic drugs. Mol Microbiol 19:1167–1175. doi:10.1111/j.1365-2958.1996.tb02462.x
Schuldiner S (2009) EmrE, a model for studying evolution and mechanism of ion-coupled transporters. Biochim Biophys Acta 1794:748–762. doi:10.1016/j.bbapap.2008.12.018
Pornillos O, Chen Y-J, Chen AP, Chang G (2005) X-ray structure of the EmrE multidrug transporter in complex with a substrate. Science 310:1950–1953. doi:10.1126/science.1119776
Chen YJ, Pornillos O, Lieu S, Ma C, Chen AP, Chang G (2007) X-ray structure of EmrE supports dual topology model. Proc Natl Acad Sci U S A 104:18999–19004. doi:10.1073/pnas.0709387104
Korkhov VM, Tate CG (2008) Electron crystallography reveals plasticity within the drug binding site of the small multidrug transporter EmrE. J Mol Biol 377:1094–1103. doi:10.1016/j.jmb.2008.01.056
Morrison EA, DeKoster GT, Dutta S, Vafabakhsh R, Clarkson MW, Bahl A, Kern D, Ha T et al (2011) Antiparallel EmrE exports drugs by exchanging between asymmetric structures. Nature 481:45–50. doi:10.1038/nature10703
Rotem D, Schuldiner S (2004) EmrE, a multidrug transporter from Escherichia coli, transports monovalent and divalent substrates with the same stoichiometry. J Biol Chem 279:48787–48793. doi:10.1074/jbc.M408187200
Venter H, Mowla R, Ohene-Agyei T, Ma S (2015) RND-type drug efflux pumps from Gram-negative bacteria: molecular mechanism and inhibition. Front Microbiol 6:377. doi:10.3389/fmicb.2015.00377
Saier M, Tam R, Reizer A, Reizer J (1994) Two novel families of bacterial membrane proteins concerned with nodulation, cell division and transport. Mol Microbiol 11:841–847. doi:10.1111/j.1365-2958.1994.tb00362.x
Nikaido H (1996) Multidrug efflux pumps of Gram-negative bacteria. J Bacteriol 178:5853–5859
Dreier J, Ruggerone P (2015) Interaction of antibacterial compounds with RND efflux pumps in Pseudomonas aeruginosa. Front Microbiol 6:660. doi:10.3389/fmicb.2015.00660
Sulavik MC, Houseweart C, Cramer C, Jiwani N, Murgolo N, Greene J, DiDomenico B, Shaw KJ et al (2001) Antibiotic susceptibility profiles of Escherichia coli strains lacking multidrug efflux pump genes. Antimicrob Agents Chemother 45:1126–1136. doi:10.1128/AAC.45.4.1126-1136.2001
Symmons MF, Bokma E, Koronakis E, Hughes C, Koronakis V (2009) The assembled structure of a complete tripartite bacterial multidrug efflux pump. Proc Natl Acad Sci U S A 106:7173–7178. doi:10.1073/pnas.0900693106
Hobbs EC, Yin X, Paul BJ, Astarita JL, Storz G (2012) Conserved small protein associates with the multidrug efflux pump AcrB and differentially affects antibiotic resistance. Proc Natl Acad Sci U S A 109:16696–16701. doi:10.1073/pnas.1210093109
Du D, Wang Z, James NR, Voss JE, Klimont E, Ohene-Agyei T, Venter H, Chiu W et al (2014) Structure of the AcrAB-TolC multidrug efflux pump. Nature 509:512–515. doi:10.1038/nature13205
Murakami S, Nakashima R, Yamashita E, Yamaguchi A (2002) Crystal structure of bacterial multidrug efflux transporter AcrB. Nature 419:587–593. doi:10.1038/nature01050
Sennhauser G, Bukowska MA, Briand C, Grutter MG (2009) Crystal structure of the multidrug exporter MexB from Pseudomonas aeruginosa. J Mol Biol 389:134–145. doi:10.1016/j.jmb.2009.04.001
Murakami S, Nakashima R, Yamashita E, Matsumoto T, Yamaguchi A (2006) Crystal structures of a multidrug transporter reveal a functionally rotating mechanism. Nature 443:173–179. doi:10.1038/nature05076
Nakashima R, Sakurai K, Yamasaki S, Nishino K, Yamaguchi A (2011) Structures of the multidrug exporter AcrB reveal a proximal multisite drug-binding pocket. Nature 480:565–569. doi:10.1038/nature10641
Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT et al (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323:1718–1722. doi:10.1126/science.1168750
Jara GE, Vera DMA, Pierini AB (2013) Binding of modulators to mouse and human multidrug resistance P-glycoprotein. A computational study. J Mol Graph Model 46:10–21. doi:10.1016/j.jmgm.2013.09.001
Wise JG (2012) Catalytic transitions in the human MDR1 P-glycoprotein drug binding sites. Biochemistry 51:5125–5141. doi:10.1021/bi300299z
Gadhe CC, Kothandan G, Joo Cho S (2013) In silico study of desmosdumotin as an anticancer agent: homology modeling, docking and molecular dynamics simulation approach. Anti-Cancer Agents Med Chem 13:1636–1644. doi:10.2174/18715206113139990302
Seeger MA, Schiefner A, Eicher T, Verrey F, Diederichs K, Pos KM (2006) Structural asymmetry of AcrB trimer suggests a peristaltic pump mechanism. Science 313:1295–1298. doi:10.1126/science.1131542
Seeger MA, Diederichs K, Eicher T, Brandstatter L, Schiefner A, Verrey F, Pos KM (2008) The AcrB efflux pump: conformational cycling and peristalsis lead to multidrug resistance. Curr Drug Targets 9:729–749. doi:10.2174/138945008785747789
Murakami S (2008) Multidrug efflux transporter, AcrB – the pumping mechanism. Curr Opin Struct Biol 18:459–465. doi:10.1016/j.sbi.2008.06.007
Nakashima R, Sakurai K, Yamasaki S, Nishino K, Yamaguchi A (2011) Structures of the multidrug exporter AcrB reveal a proximal multisite drug-binding pocket. Nature 480:565–569. doi:10.1038/nature10641
Eicher T, Cha HJ, Seeger MA, Brandstatter L, El-Delik J, Bohnert JA, Kern WV, Verrey F et al (2012) Transport of drugs by the multidrug transporter AcrB involves an access and a deep binding pocket that are separated by a switch-loop. Proc Natl Acad Sci U S A 109:5687–5692. doi:10.1073/pnas.1114944109
Pos KM (2009) Drug transport mechanism of the AcrB efflux pump. Biochim Biophys Acta 1794:782–793. doi:10.1016/j.bbapap.2008.12.015
Nikaido H, Basina M, Nguyen V, Rosenberg EY (1998) Multidrug efflux pump AcrAB of Salmonella typhimurium excretes only those β-lactam antibiotics containing lipophilic side chains. J Bacteriol 180:4686–4692
Husain F, Bikhchandani M, Nikaido H (2011) Vestibules are part of the substrate path in the multidrug efflux transporter AcrB of Escherichia coli. J Bacteriol 193:5847–5849. doi:10.1128/JB.05759-11
Wong K, Ma J, Rothnie A, Biggin PC, Kerr ID (2014) Towards understanding promiscuity in multidrug efflux pumps. Trends Biochem Sci 39:8–16. doi:10.1016/j.tibs.2013.11.002
Zechini B, Versace I (2009) Inhibitors of multidrug resistant efflux systems in bacteria. Recent Pat Antiinfect Drug Discov 4:37–50. doi:10.2174/157489109787236256
Sun J, Deng Z, Yan A (2014) Bacterial multidrug efflux pumps: mechanisms, physiology and pharmacological exploitations. Biochem Biophys Res Commun 453:254–267. doi:10.1016/j.bbrc.2014.05.090
Hirakata Y, Kondo A, Hoshino K, Yano H, Arai K, Hirotani A, Kunishima H, Yamamoto N et al (2009) Efflux pump inhibitors reduce the invasiveness of Pseudomonas aeruginosa. Int J Antimicrob Agents 34:343–346. doi:10.1016/j.ijantimicag.2009.06.007
Bhardwaj AK, Mohanty P (2012) Bacterial efflux pumps involved in multidrug resistance and their inhibitors: rejuvinating the antimicrobial chemotherapy. Recent Pat Antiinfect Drug Discov 7:73–89. doi:10.2174/157489112799829710
Grkovic S, Brown MH, Skurray RA (2002) Regulation of bacterial drug export systems. Microbiol Mol Biol Rev 66:671–701. doi:10.1128/MMBR.66.4.671-701.2002
Wilke MS, Heller M, Creagh AL, Haynes CA, McIntosh LP, Poole K, Strynadka NC (2008) The crystal structure of MexR from Pseudomonas aeruginosa in complex with its antirepressor ArmR. Proc Natl Acad Sci U S A 105:14832–14837. doi:10.1073/pnas.0805489105
Starr LM, Fruci M, Poole K (2012) Pentachlorophenol induction of the Pseudomonas aeruginosa mexAB-oprM efflux operon: involvement of repressors NalC and MexR and the antirepressor ArmR. PLoS One 7:e32684. doi:10.1371/journal.pone.0032684
Hay T, Fraud S, Lau CH, Gilmour C, Poole K (2013) Antibiotic inducibility of the mexXY multidrug efflux operon of Pseudomonas aeruginosa: involvement of the MexZ anti-repressor ArmZ. PLoS One 8:e56858. doi:10.1371/journal.pone.0056858
Purssell A, Poole K (2013) Functional characterization of the NfxB repressor of the mexCD-oprJ multidrug efflux operon of Pseudomonas aeruginosa. Microbiology 159:2058–2073. doi:10.1099/mic.0.069286-0
Lau CH, Hughes D, Poole K (2014) MexY-promoted aminoglycoside resistance in Pseudomonas aeruginosa: involvement of a putative proximal binding pocket in aminoglycoside recognition. mBio 5:e01068–14. doi:10.1128/mBio.01068-14
Lomovskaya O, Lewis K, Matin A (1995) EmrR is a negative regulator of the Escherichia coli multidrug resistance pump EmrAB. J Bacteriol 177:2328–2334
Rice A, Liu Y, Michaelis ML, Himes RH, Georg GI, Audus KL (2005) Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood-brain barrier in vitro and in situ. J Med Chem 48:832–838. doi:10.1021/jm040114b
Chopra I (2002) New developments in tetracycline antibiotics: glycylcyclines and tetracycline efflux pump inhibitors. Drug Resist Updat 5:119–125. doi:10.1016/S1368-7646(02)00051-1
Chollet R, Chevalier J, Bryskier A, Pagès JM (2004) The AcrAB-TolC pump is involved in macrolide resistance but not in telithromycin efflux in Enterobacter aerogenes and Escherichia coli. Antimicrob Agents Chemother 48:3621–3624. doi:10.1128/AAC.48.9.3621-3624.2004
Hooper DC (2000) Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis 31(Suppl 2):S24–S28. doi:10.1086/314056
Pagès JM, Masi M, Barbe J (2005) Inhibitors of efflux pumps in Gram-negative bacteria. Trends Mol Med 11:382–389. doi:10.1016/j.molmed.2005.06.006
Marquez B (2005) Bacterial efflux systems and efflux pumps inhibitors. Biochimie 87:1137–1147. doi:10.1016/j.biochi.2005.04.012
Lynch AS (2006) Efflux systems in bacterial pathogens: an opportunity for therapeutic intervention? An industry view. Biochem Pharmacol 71:949–956. doi:10.1016/j.bcp.2005.10.021
Mahamoud A, Chevalier J, Alibert-Franco S, Kern WV, Pagès J-M (2007) Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy. J Antimicrob Chemother 59:1223–1229. doi:10.1093/jac/dkl493
Nakashima R, Sakurai K, Yamasaki S, Hayashi K, Nagata C, Hoshino K, Onodera Y, Nishino K et al (2013) Structural basis for the inhibition of bacterial multidrug exporters. Nature 500:102–106. doi:10.1038/nature12300
Opperman TJ, Kwasny SM, Kim HS, Nguyen ST, Houseweart C, D'Souza S, Walker GC, Peet NP et al (2014) Characterization of a novel pyranopyridine inhibitor of the AcrAB efflux pump of Escherichia coli. Antimicrob Agents Chemother 58:722–733. doi:10.1128/AAC.01866-13
Nguyen ST, Kwasny SM, Ding X, Cardinale SC, McCarthy CT, Kim H-S, Nikaido H, Peet NP et al (2015) Structure–activity relationships of a novel pyranopyridine series of Gram-negative bacterial efflux pump inhibitors. Bioorg Med Chem 23:2024–2034. doi:10.1016/j.bmc.2015.03.016
Opperman TJ, Nguyen ST (2015) Recent advances toward a molecular mechanism of efflux pump inhibition. Front Microbiol 6:421. doi:10.3389/fmicb.2015.00421
Viveiros M, Jesus A, Brito M, Leandro C, Martins M, Ordway D, Molnar AM, Molnar J et al (2005) Inducement and reversal of tetracycline resistance in Escherichia coli K-12 and expression of proton gradient-dependent multidrug efflux pump genes. Antimicrob Agents Chemother 49:3578–3582. doi:10.1128/AAC.49.8.3578-3582.2005
Martins M, Dastidar SG, Fanning S, Kristiansen JE, Molnar J, Pagès JM, Schelz Z, Spengler G et al (2008) Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities. Int J Antimicrob Agents 31:198–208. doi:10.1016/j.ijantimicag.2007.10.025
Li X-Z, Nikaido H (2004) Efflux-mediated drug resistance in bacteria. Drugs 64:159–204. doi:10.2165/00003495-200464020-00004
Kourtesi C, Ball AR, Huang Y-Y, Jachak SM, Vera DMA, Khondkar P, Gibbons S, Hamblin MR et al (2013) Microbial efflux systems and inhibitors: approaches to drug discovery and the challenge of clinical implementation. Open Microbiol J 7:34–52. doi:10.2174/1874285801307010034
Tikhonova EB, Yamada Y, Zgurskaya HI (2011) Sequential mechanism of assembly of multidrug efflux pump AcrAB-TolC. Chem Biol 18:454–463. doi:10.1016/j.chembiol.2011.02.011
Zeng B, Wang H, Zou L, Zhang A, Yang X, Guan Z (2010) Evaluation and target validation of indole derivatives as inhibitors of the AcrAB-TolC efflux pump. Biosci Biotechnol Biochem 74:2237–2241. doi:10.1271/bbb.100433
Andersen C, Koronakis E, Hughes C, Koronakis V (2002) An aspartate ring at the TolC tunnel entrance determines ion selectivity and presents a target for blocking by large cations. Mol Microbiol 44:1131–1139. doi:10.1046/j.1365-2958.2002.02898.x
Chevalier J, Mulfinger C, Garnotel E, Nicolas P, Davin-Regli A, Pagès JM (2008) Identification and evolution of drug efflux pump in clinical Enterobacter aerogenes strains isolated in 1995 and 2003. PLoS One 3:e3203. doi:10.1371/journal.pone.0003203
Yamaguchi A, Nakashima R, Sakurai K (2015) Structural basis of RND-type multidrug exporters. Front Microbiol 6:327. doi:10.3389/fmicb.2015.00327
Du D, van Veen HW, Luisi BF (2015) Assembly and operation of bacterial tripartite multidrug efflux pumps. Trends Microbiol 23:311–319. doi:10.1016/j.tim.2015.01.010
Van Bambeke F, Lee VJ (2006) Inhibitors of bacterial efflux pumps as adjuvants in antibiotic treatments and diagnostic tools for detection of resistance by efflux. Recent Pat Antiinfect Drug Discov 1:157–175. doi:10.2174/157489106777452692
Schwede T, Peitsch M (2008) Computational structural biology: methods and applications. World Scientific Publishing Co. Pte. Ltd., Singapore
Halperin I, Ma B, Wolfson H, Nussinov R (2002) Principles of docking: an overview of search algorithms and a guide to scoring functions. Proteins 47:409–443. doi:10.1002/prot.10115
van Dijk AD, Boelens R, Bonvin AM (2005) Data‐driven docking for the study of biomolecular complexes. FEBS J 272:293–312. doi:10.1111/j.1742-4658.2004.04473.x
van Dijk AD, Bonvin AM (2006) Solvated docking: introducing water into the modelling of biomolecular complexes. Bioinformatics 22:2340–2347. doi:10.1093/bioinformatics/btl395
Martí-Renom MA, Stuart AC, Fiser A, Sánchez R, Melo F, Šali A (2000) Comparative protein structure modeling of genes and genomes. Ann Rev Biophys Biomol Struct 29:291–325. doi:10.1146/annurev.biophys.29.1.291
Šali A, Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234:779–815. doi:10.1006/jmbi.1993.1626
Eswar N, Webb B, Marti‐Renom MA, Madhusudhan M, Eramian D, Shen M, Pieper U, Sali A (2006) Comparative protein structure modeling using Modeller. Curr Protoc Bioinformatics 15:5.6.1–5.6.30. doi:10.1002/0471250953.bi0506s15
Salam NK, Nuti R, Sherman W (2009) Novel method for generating structure-based pharmacophores using energetic analysis. J Chem Inf Model 49:2356–2368. doi:10.1021/ci900212v
Joseph-McCarthy D (1999) Computational approaches to structure-based ligand design. Pharmacol Ther 84:179–191. doi:10.1016/S0163-7258(99)00031-5
Lyne PD (2002) Structure-based virtual screening: an overview. Drug Discov Today 7:1047–1055. doi:10.1016/S1359-6446(02)02483-2
Galeazzi R (2009) Molecular dynamics as a tool in rational drug design: current status and some major applications. Curr Comput Aided Drug Des 5:225–240. doi:10.2174/157340909789577847
Ferreira RJ, Ferreira M-JU, dos Santos DJ (2012) Insights on P-glycoprotein’s efflux mechanism obtained by molecular dynamics simulations. J Chem Theory Comput 8:1853–1864. doi:10.1021/ct300083m
Ruggerone P, Vargiu AV, Collu F, Fischer N, Kandt C (2013) Molecular dynamics computer simulations of multidrug RND efflux pumps. Comput Struct Biotechnol J 5:e201302008. doi:10.5936/csbj.201302008
Schlitter J, Engels M, Krüger P (1994) Targeted molecular dynamics: a new approach for searching pathways of conformational transitions. J Mol Graph 12:84–89. doi:10.1016/0263-7855(94)80072-3
Izvekov S, Voth GA (2005) A multiscale coarse-graining method for biomolecular systems. J Phys Chem B 109:2469–2473. doi:10.1021/jp044629q
Takada S (2012) Coarse-grained molecular simulations of large biomolecules. Curr Opin Struct Biol 22:130–137. doi:10.1016/j.sbi.2012.01.010
Parkin J, Chavent M, Khalid S (2015) Molecular simulations of Gram-negative bacterial membranes: a vignette of some recent successes. Biophys J 109:461–468. doi:10.1016/j.bpj.2015.06.050
Collu F, Cascella M (2013) Multidrug resistance and efflux pumps: insights from molecular dynamics simulations. Curr Top Med Chem 13:3165–3183. doi:10.2174/15680266113136660224
Ohene‐Agyei T, Mowla R, Rahman T, Venter H (2014) Phytochemicals increase the antibacterial activity of antibiotics by acting on a drug efflux pump. Microbiol Open 3:885–896. doi:10.1002/mbo3.212
Aparna V, Dineshkumar K, Mohanalakshmi N, Velmurugan D, Hopper W (2014) Identification of natural compound inhibitors for multidrug efflux pumps of Escherichia coli and Pseudomonas aeruginosa using in silico high-throughput virtual screening and in vitro validation. PLoS One 9:e101840. doi:10.1371/journal.pone.0101840
Takatsuka Y, Chen C, Nikaido H (2010) Mechanism of recognition of compounds of diverse structures by the multidrug efflux pump AcrB of Escherichia coli. Proc Natl Acad Sci U S A 107:6559–6565. doi:10.1073/pnas.1001460107
Vargiu AV, Nikaido H (2012) Multidrug binding properties of the AcrB efflux pump characterized by molecular dynamics simulations. Proc Natl Acad Sci U S A 109:20637–20642. doi:10.1073/pnas.1218348109
Vargiu AV, Ruggerone P, Opperman TJ, Nguyen ST, Nikaido H (2014) Molecular mechanism of MBX2319 inhibition of Escherichia coli AcrB multidrug efflux pump and comparison with other inhibitors. Antimicrob Agents Chemother 58:6224–6234. doi:10.1128/AAC.03283-14
Feng Z, Hou T, Li Y (2012) Unidirectional peristaltic movement in multisite drug binding pockets of AcrB from molecular dynamics simulations. Mol Biosyst 8:2699–2709. doi:10.1039/c2mb25184a
Vargiu AV, Collu F, Schulz R, Pos KM, Zacharias M, Kleinekathofer U, Ruggerone P (2011) Effect of the F610A mutation on substrate extrusion in the AcrB transporter: explanation and rationale by molecular dynamics simulations. J Am Chem Soc 133:10704–10707. doi:10.1021/ja202666x
Bohnert JA, Schuster S, Seeger MA, Fahnrich E, Pos KM, Kern WV (2008) Site-directed mutagenesis reveals putative substrate binding residues in the Escherichia coli RND efflux pump AcrB. J Bacteriol 190:8225–8229. doi:10.1128/JB.00912-08
Sjuts H, Vargiu AV, Kwasny SM, Nguyen ST, Kim H-S, Ding X, Ornik AR, Ruggerone P et al (2016) Molecular basis for inhibition of AcrB multidrug efflux pump by novel and powerful pyranopyridine derivatives. Proc Natl Acad Sci U S A 113:3509–3514. doi:10.1073/pnas.1602472113
Yilmaz S, Altinkanat-Gelmez G, Bolelli K, Guneser-Merdan D, Ufuk Over-Hasdemir M, Aki-Yalcin E, Yalcin I (2015) Binding site feature description of 2-substituted benzothiazoles as potential AcrAB-TolC efflux pump inhibitors in E. coli. SAR QSAR Environ Res 26:853–871. doi:10.1080/1062936X.2015.1106581
Kinana AD, Vargiu AV, May T, Nikaido H (2016) Aminoacyl β-naphthylamides as substrates and modulators of AcrB multidrug efflux pump. Proc Natl Acad Sci U S A 113:1405–1410. doi:10.1073/pnas.1525143113
van Veen HW, Venema K, Bolhuis H, Oussenko I, Kok J, Poolman B, Driessen AJ, Konings WN (1996) Multidrug resistance mediated by a bacterial homolog of the human multidrug transporter MDR1. Proc Natl Acad Sci U S A 93:10668–10672
Reuter G, Janvilisri T, Venter H, Shahi S, Balakrishnan L, van Veen HW (2003) The ATP binding cassette multidrug transporter LmrA and lipid transporter MsbA have overlapping substrate specificities. J Biol Chem 278:35193–35198. doi:10.1074/jbc.M306226200
Davidson AL, Dassa E, Orelle C, Chen J (2008) Structure, function, and evolution of bacterial ATP-binding cassette systems. Microbiol Mol Biol Rev 72:317–364. doi:10.1128/MMBR.00031-07
Vandevuer S, Van Bambeke F, Tulkens PM, Prévost M (2006) Predicting the three‐dimensional structure of human P‐glycoprotein in absence of ATP by computational techniques embodying crosslinking data: insight into the mechanism of ligand migration and binding sites. Proteins 63:466–478. doi:10.1002/prot.20892
Pajeva IK, Wiese M (2002) Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis). J Med Chem 45:5671–5686. doi:10.1021/jm020941h
Klepsch F, Chiba P, Ecker GF (2011) Exhaustive sampling of docking poses reveals binding hypotheses for propafenone type inhibitors of P-glycoprotein. PLoS Comput Biol 7:e1002036. doi:10.1371/journal.pcbi.1002036
Liu M, Hou T, Feng Z, Li Y (2013) The flexibility of P-glycoprotein for its poly-specific drug binding from molecular dynamics simulations. J Biomol Struct Dyn 31:612–629. doi:10.1080/07391102.2012.706079
Ma J, Biggin PC (2013) Substrate versus inhibitor dynamics of P‐glycoprotein. Proteins 81:1653–1668. doi:10.1002/prot.24324
Dawson RJP, Locher KP (2006) Structure of a bacterial multidrug ABC transporter. Nature 443:180–185. doi:10.1038/nature05155
Prajapati R, Sangamwar AT (2014) Translocation mechanism of P-glycoprotein and conformational changes occurring at drug-binding site: insights from multi-targeted molecular dynamics. Biochim Biophys Acta 1838:2882–2898. doi:10.1016/j.bbamem.2014.07.018
Tardia P, Stefanachi A, Niso M, Stolfa DA, Mangiatordi GF, Alberga D, Nicolotti O, Lattanzi G et al (2014) Trimethoxybenzanilide-based P-glycoprotein modulators: an interesting case of lipophilicity tuning by intramolecular hydrogen bonding. J Med Chem 57:6403–6418. doi:10.1021/jm500697c
Singh S, Mandlik V (2015) Structure based investigation on the binding interaction of transport proteins in leishmaniasis: insights from molecular simulation. Mol Biol Syst 11:1251–1259. doi:10.1039/c4mb00713a
Tomkiewicz D, Casadei G, Larkins-Ford J, Moy TI, Garner J, Bremner JB, Ausubel FM, Lewis K et al (2010) Berberine-INF55 (5-nitro-2-phenylindole) hybrid antimicrobials: effects of varying the relative orientation of the berberine and INF55 components. Antimicrob Agents Chemother 54:3219–3224. doi:10.1128/AAC.01715-09
Acknowledgments
The research leading to the results discussed here was partly conducted as part of the Translocation Consortium (http://www.translocation.eu) and has received support from the Innovative Medicines Initiative Joint Undertaking under Grant Agreement no. 115525, resources that are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007–2013) and EFPIA companies in kind contribution.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Ramaswamy, V.K., Cacciotto, P., Malloci, G., Ruggerone, P., Vargiu, A.V. (2016). Multidrug Efflux Pumps and Their Inhibitors Characterized by Computational Modeling. In: Li, XZ., Elkins, C., Zgurskaya, H. (eds) Efflux-Mediated Antimicrobial Resistance in Bacteria. Adis, Cham. https://doi.org/10.1007/978-3-319-39658-3_30
Download citation
DOI: https://doi.org/10.1007/978-3-319-39658-3_30
Published:
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-39656-9
Online ISBN: 978-3-319-39658-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)